Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Case series:Anlotinib capsule combined with tirelizumab, paclitaxel liposome and nedaplatin
2 trials
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Conditions
Esophageal cancer
Early Phase 1
Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma
Active, not recruiting
ChiCTR2100049693
The First Affiliated Hospital of Guangxi Medical University
Esophageal cancer
Start: 2021-09-01
Updated: 2022-04-19
Phase 2
Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma
Recruiting
ChiCTR2100043836
The First Affiliated Hospital of Guangxi Medical University
Esophageal cancer
Start: 2021-04-01
Updated: 2021-07-05
Related Papers
Anlotinib hydrochloride combined with tislelizumab, paclitaxel liposome, and nedaplatin regimen for preoperative neoadjuvant therapy of esophageal cancer: A single-arm, single-center, phase II exploratory clinical study.
Journal of Clinical Oncology
2023-06-01